XALKORI® (crizotinib): ALK and ROS1 testing

When to test:

At diagnosis of advanced-stage disease1,2

Who to test:

ESMO:3

Systematically in advanced non-squamous cell carcinoma and in patients with squamous cell carcinoma who are never or former light smokers (<15 pack years).
Test results should be available within 10 working days.1

How to support your patients with ALK testing

 

References:
1. Leighl NB, et al. Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline. J Clin Oncol. 2014;32:3673–3679.
2. XALKORI® Summary of Product Characterstics
3. Planchard D, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2018: 29(supplement 4):iv192-iv237. doi:10.1093/annonc/mdy275
4. Cancer Research UK. (2015). Molecular Diagnostic Provision in England, for targeted solid tumours in the NHS. Available at: www.cancerresearchuk.org/sites/default/files/policy_august2015_mdx_final....
5. Kris MG et al. (2011). Identification of driver mutations in tumor specimens from 1000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC).
6. Solomon BJ, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–2177.
7. Shaw AT et al. (2013). Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer. The New England Journal of Medicine. (368), 2385–94.
8. Kerr K et al. (2014). Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Annals of Oncology. (25), 1681–90.
9. Monitor (2016) 2016/17 National Tariff Payment System: A consultation notice. Available at:www.gov.uk/government/uploads/system/uploads/attachment_data/file/499594....

PP-XLK-GBR-1135. March 2020

Pfizer at the Annual BTOG (British Thoracic Oncology Group) Conference

January 23rd – 25th 2019

Pfizer Healthcare Sales Representatives carried out a survey with over 30 Healthcare Professionals to gain insight into ROS1 testing across the UK, where it was discovered that…

  • 37.5% of delegates routinely test ALL advanced NSCLC patients for ROS1
  • 1 in 2* are not informed of national ROS1 testing centres

*46.88% of those delegates that answered the survey

When to test:

At diagnosis of NSCLC alongside EGFR and ALK testing1,2

Who to test:

ESMO:3

  • Testing for ROS1 rearrangement should be systematically carried out in all patients with advanced NSCLC
  • Never or former light smokers (<15 pack years) in patients with advanced squamous cell carcinoma

CAP-IASLC-AMP Guidlines:4

All patients with advanced adenocarcinoma of the lung irrespective of clinical characteristics.

References:
1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-small cell lung cancer – Version 7.2017.
2. Budendorf L, et al. Testing for ROS1 in non-small cell lung cancer: a review with recommendations. Virchows Arch. 2016;469(5):489–503.
3. Planchard D, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2018: 29(supplement 4):iv192-iv237. doi:10.1093/annonc/mdy275
4. Lindeman NI, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. the Journal of Molecular Diagnostics, Vol. 20, No. 2, March 2018

PP-XLK-GBR-1120. October 2019